文献速递慢阻肺呼吸道感染

气道真菌组高危特征与慢阻肺频繁急性加重及死亡率相关

A high-risk airway mycobiome is associated with frequent exacerbation and mortality in COPD.
PubMed 文献 · Eur Respir J · 2021-03-11

本研究纳入亚洲和英国的多中心稳定期慢阻肺患者(n=337)、急性加重期患者(n=66)及健康对照(n=47),分析气道真菌组与急性加重频率、2年死亡率及真菌特异性IgE的关系。结果显示慢阻肺患者真菌α多样性和交互作用增强,特定真菌属(曲霉、弯孢、青霉)与频繁急性加重和高死亡率相关,急性加重期真菌多样性降低与2年死亡率升高相关。

要点

  • 慢阻肺患者气道真菌组α多样性高于健康对照。
  • 每年≥3次急性加重者真菌组间交互作用显著增强。
  • 曲霉、弯孢、青霉优势集群伴特异IgE升高者急性加重频繁且死亡率高。

核心结论

  • 慢阻肺气道真菌组存在特定真菌属,与急性加重频率和死亡率增加相关。

研究设计与样本

  • 多中心观察性研究,纳入稳定期慢阻肺患者n=337、急性加重期n=66、健康对照n=47,来自亚洲和英国。
  • 对34例患者进行急性加重期及治疗后纵向真菌组分析。

主要发现

  • 慢阻肺患者真菌α多样性(Shannon指数)较对照增高(p<0.001)。
  • 每年≥3次急性加重者真菌组差异显著(置换多元方差分析,校正p<0.001)。
  • 急性加重期抗生素和皮质激素治疗后真菌组无显著变化。
  • 无监督聚类识别出两个临床亚群:一个症状评分高且酵母菌优势,另一个频繁急性加重且死亡率高,以曲霉、弯孢、青霉为主伴相应血清sIgE升高。
  • 急性加重期真菌多样性较低与2年死亡率较高相关。

临床怎么用

  • 对频繁急性加重慢阻肺患者可考虑评估气道真菌组及真菌特异性IgE。
  • 急性加重期真菌多样性低可能提示预后不良,需加强随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The chronic obstructive pulmonary disease (COPD) bacteriome associates with disease severity, exacerbations and mortality. While COPD patients are susceptible to fungal sensitisation, the role of the fungal mycobiome remains uncertain. METHODS: We report the largest multicentre evaluation of the COPD airway mycobiome to date, including participants from Asia (Singapore and Malaysia) and the UK (Scotland) when stable (n=337) and during exacerbations (n=66) as well as nondiseased (healthy) controls (n=47). Longitudinal mycobiome analysis was performed during and following COPD exacerbations (n=34), and examined in terms of exacerbation frequency, 2-year mortality and occurrence of serum specific IgE (sIgE) against selected fungi. RESULTS: A distinct mycobiome profile is observed in COPD compared with controls as evidenced by increased α-diversity (Shannon index; p<0.001). Significant airway mycobiome differences, including greater interfungal interaction (by co-occurrence), characterise very frequent COPD exacerbators (three or more exacerbations per year) (permutational multivariate ANOVA; adjusted p<0.001). Longitudinal analyses during exacerbations and following treatment with antibiotics and corticosteroids did not reveal any significant change in airway mycobiome profile. Unsupervised clustering resulted in two clinically distinct COPD groups: one with increased symptoms (COPD Assessment Test score) and Saccharomyces dominance, and another with very frequent exacerbations and higher mortality characterised by Aspergillus, Curvularia and Penicillium with a concomitant increase in serum sIgE levels against the same fungi. During acute exacerbations of COPD, lower fungal diversity associates with higher 2-year mortality. CONCLUSION: The airway mycobiome in COPD is characterised by specific fungal genera associated with exacerbations and increased mortality.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Tiew PY, Dicker AJ, Keir HR, et al. A high-risk airway mycobiome is associated with frequent exacerbation and mortality in COPD. Eur Respir J. 2021. PMID: 32972986. doi:10.1183/13993003.02050-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。